GB 3226
Alternative Names: BRM-1420; GB-3226Latest Information Update: 20 Nov 2025
At a glance
- Originator Rockefeller University
- Developer Galecto Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 10 Nov 2025 Galecto receives constructive feedback from the US FDA in response to its pre-Investigational New Drug (pre-IND) submission
- 03 Nov 2025 Pharmacokinetics and adverse events data from preclinical studies in Acute myeloid leukaemia (AML) released by Galecto
- 24 Jul 2025 Galecto plans a phase I/II trial for Acute myeloid leukaemia (Second-line therapy or greater) (PO), in June 2026 (NCT07084584)